Dialysis systems comprising actuators that cooperate to perform dialysis functions and sensors that cooperate to monitor dialysis functions are disclosed. According to one aspect, such a hemodialysis system comprises a user interface model layer, a therapy layer, below the user interface model layer, and a machine layer below the therapy layer. The user interface model layer is configured to manage the state of a graphical user interface and receive inputs from a graphical user interface. The therapy layer is configured to run state machines that generate therapy commands based at least in part on the inputs from the graphical user interface. The machine layer is configured to provide commands for the actuators based on the therapy commands.

A portable ultrafiltration device having a suction bellows connected to a tube, passing through a solenoid valve, to a first dialysate connector of a hemofilter incorporated into a blood circuit having arterial lines, extending from a vascular access and passing through a peristaltic pump, and venous lines passing through an electronic safety block to the vascular access, and a second dialysate connector connected to an ultrafiltration pressure sensor. The elements of the portable ultrafiltration device are connected and controlled by an intelligent central unit powered by a rechargeable battery. Liquid collects in the space surrounding the fibres and in the suction bellows until the space is completely full.

The invention relates to a dialysis machine having an extracorporeal blood circuit, a blood pump, a dialyzer, a venous pressure sensor, a substituate line, and a control unit, wherein the control unit is configured to operate the blood pump in a first operating mode and in a special operating mode and to start the special operating mode after recognition of a trigger event, in which special operating mode a conveying rate of the blood pump is controlled by means of a default value or is regulated to a desired value, which default or desired value is derived from a value determined before the start of the currently started special operating mode or corresponds to said value, wherein the presence of at least one obstacle is polled before the start of the special operating mode, and wherein, on the presence of the obstacle, the start of the special operating mode is blocked or delayed and/or the selection of the default value or of the desire value on the presence of the obstacle differs from the selection without the presence of the obstacle.

The disclosed subject matter relates to extracorporeal blood processing or other processing of fluids. Volumetric fluid balance, a required element of many such processes, may be achieved with multiple pumps or other proportioning or balancing devices which are to some extent independent of each other. This need may arise in treatments that involve multiple fluids. Safe and secure mechanisms to ensure fluid balance in such systems are described.

A method for extracorporeal blood treatment using a medical device including at least a dialyzer device, with the following steps: start of blood treatment by means of hemodialysis on the basis of default values for the hemodialysis; determination of current values or ratios of at least one blood flow, an ultrafiltration quantity, a substitution quantity or a type of substitution; recording of a therapy progress on the basis of an output signal of a sensor means; determination of a time of formation of a secondary membrane on the dialyzer by determination of a cross rate in the dialyzer device; change from the hemodialysis to a hemodiafiltration with post-dilution after a predetermined period of time has elapsed; and regulation of the substitution quantity during hemodiafiltration with post-dilution. Corresponding tools for carrying out the method are arranged in a device for extracorporeal blood treatment.

The present invention relates to a method and to an apparatus for predicting one or more parameters characteristic for the outcome of a blood treatment, wherein the blood treatment is a treatment in which the blood of the patient has fluid removed via at least one membrane, wherein the parameters are the allowed drinking volume, the hyperhydration or hypohydration of the patient, the clearance of large molecules and/or the allowed salt intake, wherein the prediction of the allowed drinking volume and the prediction of the hyperhydration or hypohydration are carried out on the basis of the planned weight loss due to ultrafiltration, of the drinking quantity during the treatment, of the rinseback volume and of residual diuresis data, and/or wherein the prediction of the clearance of large molecules is carried out on the basis of the urea clearance, and/or wherein the prediction of the allowed salt intake takes place based on the sodium ion quantity removed by ultrafiltration and by diffusion from the blood.

An example renal therapy system includes a blood pressure monitor configured to output blood pressure data concerning a patient and a renal therapy machine communicatively coupled to the blood pressure monitor. The renal therapy machine is configured to generate ultrafiltration (“UF”) removed data from a prescribed renal therapy treatment performed by the renal therapy machine on the patient, and transmit the UF removed data and the blood pressure data via a network. At least one of a UF trend or a blood pressure trend from the UF removed data or the blood pressure data is determined, enabling a further determination as to at least one of (a) whether a prescribed renal therapy treatment adjustment or a new prescribed renal therapy treatment needs to be made, (b) whether the patient is complying with the prescribed renal therapy treatment, or (c) whether a condition related to an alarm or an alert exists.

A control and/or regulation device, which is connected via signal link to a first input device, which in particular is operable by a doctor, and to a second input device, which in particular is operable by a patient, wherein the control or regulation device is programmed to control and/or regulate in signal link with a blood treatment

The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.

Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half-life of the protein for treating wounds.